A Phase 1 Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Mipomersen (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacodynamics
- Sponsors Kastle Therapeutics
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 25 May 2012 Planned end date changed from 1 Apr 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 25 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.